ArticleOdontology2020
Tripartite motif 31 alleviates IL-1ß secretion via promoting the ubiquitination of pyrin domain domains-containing protein 3 in human periodontal ligament fibroblasts.
Article in Odontology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Loss of Trim31 Worsens Cardiac Remodeling in a Mouse Model of Heart Failure by Enhancing the Activation of the NLRP3 Inflammasome.Inflammation · 2025Article
- NLRP10 promotes AGEs-induced NLRP1 and NLRP3 inflammasome activation via ROS/MAPK/NF-κB signaling in human periodontal ligament cells.Odontology · 2024Article
- Role of NLRP3 inflammasome-mediated neuronal pyroptosis and neuroinflammation in neurodegenerative diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Review
- TRIMs: Generalists Regulating the NLRP3 Inflammasome Signaling Pathway.DNA and cell biology · 2022Review
- Mechanisms of bone remodeling and therapeutic strategies in chronic apical periodontitis.Frontiers in cellular and infection microbiology · 2022Review
- TRIM31: A molecule with a dual role in cancer.Frontiers in oncology · 2022Review
- NLRP3 regulates alveolar bone loss in ligature-induced periodontitis by promoting osteoclastic differentiation.Cell proliferation · 2021Article
- Emerging Roles of MHC Class I Region-Encoded E3 Ubiquitin Ligases in Innate Immunity.Frontiers in immunology · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apical periodontitis (AP) is an inflammatory disease caused by bacteria infection and is regarded as a common disease in the world. In the progression of AP, the function of nucleotide-binding oligomerization, leucine-rich repeat and pyrin domain domains-containing protein 3 (NLRP3) inflammasome has been revealed. Although tripartite motif 31 (TRIM31) has been suggested to regulate many chronic inflammations by mediating NLRP3 inflammasome, such mechanism in AP remains unclear. In this study, co-treatment of human periodontal ligament fibroblasts (HPDLFs) with lipopolysaccharides (LPS) and adenosine triphosphate (ATP) were conducted to establish AP cell model. ELISA assay was used to measure the concentration of secretive interleukin 1 beta (IL-1β). In addition, the expression levels of NLRP3 after TRIM31 up- or down-regulation were detected by real-time PCR and western blot. Immunoprecipitation was used to explore the interaction between TRIM31 and NLRP3. We found that co-treatment with LPS and ATP increased the secretion of IL-1β and expression of NLRP3 in HPDLFs, while TRIM31 overexpression could reverse these effects caused by LPS and ATP. Furthermore, the interaction between TRIM31 and NLRP3 was observed, and TRIM31 was found to promote the ubiquitination of NLRP3. TRIM31 may alleviate IL-1ß secretion caused by LPS and ATP via promoting the ubiquitination of NLRP3 and may exert an influence on the development of AP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.